Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 15/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.52 |
| ▸ | STAT3 | P40763 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850714 | 0.88 | DDB1 (0.63) | DDB1CRBNSTAT3 | |
| SCHEMBL20850806 | 0.87 | CRBN (0.57) | DDB1CRBN | |
| SCHEMBL20840373 | 0.84 | CRBN (0.58) | DDB1CRBN | |
| SCHEMBL31729996 | 0.83 | DDB1 (0.58) | DDB1CRBNSTAT3 | |
| SCHEMBL26099077 | 0.81 | CRBN (0.49) | DDB1CRBNSTAT3 | |
| SCHEMBL26099776 | 0.79 | CRBN (0.61) | DDB1CRBNSTAT3 | |
| SCHEMBL26098753 | 0.79 | CRBN (0.61) | DDB1CRBNSTAT3 | |
| SCHEMBL20840314 | 0.79 | CRBN (0.60) | DDB1CRBNSTAT3 | |
| SCHEMBL20840210 | 0.79 | CRBN (0.60) | DDB1CRBNSTAT3 | |
| SCHEMBL20840317 | 0.79 | CRBN (0.60) | DDB1CRBNSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11623932-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3684365-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060742-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115184-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
| US-11623932-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | DDB1 660/4885CRBN 7/4885STAT3 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.